Proteomics

Dataset Information

0

Development of novel combination treatments in AML guided by proteomics profiling


ABSTRACT: Acute promyelocytic leukaemia (APL) can be cured by the co-administration of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA). These small molecules relieve the differentiation blockade of the cancerous promyelocytes and trigger their maturation into functional neutrophils, which are physiologically primed for apoptosis. This normalization therapy uses low dose treatments and represents a compelling alternative to cytotoxic anticancer chemotherapy. However, the serendipitous discovery of this combination treatment prevented the establishment of methodologies to screen for novel combination treatments consisting of inducers of differentiation and other metallopharmaceuticals. Here, we present an experimental framework that enables interrogating the suitability, directionality and extent of normalization of novel combination treatments. Since the endpoint of this anticancer treatment is remodelling of cancer phenotypes, this approach requires a mechanism-driven understanding of the drug-induced cellular adaptions along the path to mature neutrophils. For this purpose, label-free quantification proteomics is used to probe the proteome changes upon differentiation and metal(-loid) treatment on the molecular level in a panel of ATRA-responsive and ATRA-non-responsive acute myeloid leukaemia (AML) cell lines, including APL. The induction of differentiation was confirmed by the up-regulation of canonical surface markers (e.g. CD11β) and validated by flow cytometry. The regulation of key transcription factors in this panel of AML cell lines reflects their position in the myeloid differentiation cascade (e.g. SPI1, GFI-1 and CEBPE). The additive/synergistic contributions of ATO to the combination treatment were thoroughly characterized and include changes in metabolic activities, as well as protein signatures related to management of reactive oxygen species and an integrated stress response. The latter two are also characteristic for the organoruthenium-based drug candidate plecstatin-1, which was recently shown to modulate the scaffold protein plectin. The combination of differentiation-induction and plecstatin-1 treatment featured a striking similarity in the responsiveness of the AML cancer cells compared to ATO+ATRA. It turned out to be at least equivalent in the regulation of key processes underlying normalization therapy in AML with granulocytic maturation. By exploiting response patterns of AML cancer cells induced by the ATO+ATRA combination treatment, this approach may allow identifying novel small molecule combinations, which may have the potential to achieve normalization and thus therapeutic benefit beyond APL.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Monocyte, Cell Culture

DISEASE(S): Acute Leukemia

SUBMITTER: Christopher Gerner  

LAB HEAD: Christopher Gerner

PROVIDER: PXD019619 | Pride | 2022-02-22

REPOSITORIES: Pride

altmetric image

Publications

A Proteomic Platform Enables to Test for AML Normalization <i>In Vitro</i>.

Meier-Menches Samuel M SM   Neuditschko Benjamin B   Janker Lukas L   Gerner Marlene C MC   Schmetterer Klaus G KG   Reichle Albrecht A   Gerner Christopher C  

Frontiers in chemistry 20220201


Acute promyelocytic leukaemia (APL) can be cured by the co-administration of arsenic trioxide (ATO) and all-<i>trans</i> retinoic acid (ATRA). These small molecules relieve the differentiation blockade of the transformed promyelocytes and trigger their maturation into functional neutrophils, which are physiologically primed for apoptosis. This normalization therapy represents a compelling alternative to cytotoxic anticancer chemotherapy, but lacks an <i>in vitro</i> model system for testing the  ...[more]

Similar Datasets

2012-08-29 | E-GEOD-30254 | biostudies-arrayexpress
2012-03-14 | E-GEOD-34672 | biostudies-arrayexpress
2017-05-12 | GSE90062 | GEO
2010-12-01 | E-GEOD-23702 | biostudies-arrayexpress
2012-03-14 | E-GEOD-34725 | biostudies-arrayexpress
2012-03-14 | GSE34725 | GEO
2012-03-14 | GSE34672 | GEO
2018-10-16 | PXD010224 | Pride
2017-07-06 | GSE94017 | GEO
2017-05-12 | GSE95637 | GEO